These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 23009088)

  • 1. Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present).
    Sacco E; Spinelli M; Vanoni M
    Expert Opin Ther Pat; 2012 Nov; 22(11):1263-87. PubMed ID: 23009088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RAS: target for cancer therapy.
    Saxena N; Lahiri SS; Hambarde S; Tripathi RP
    Cancer Invest; 2008 Nov; 26(9):948-55. PubMed ID: 18798058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel mitogen-activated protein kinase kinase inhibitors.
    Chapman MS; Miner JN
    Expert Opin Investig Drugs; 2011 Feb; 20(2):209-20. PubMed ID: 21235429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer targets in the Ras pathway.
    Rodriguez-Viciana P; Tetsu O; Oda K; Okada J; Rauen K; McCormick F
    Cold Spring Harb Symp Quant Biol; 2005; 70():461-7. PubMed ID: 16869784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP inhibitors in cancer therapy: an update.
    Papeo G; Casale E; Montagnoli A; Cirla A
    Expert Opin Ther Pat; 2013 Apr; 23(4):503-14. PubMed ID: 23379721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways.
    Lackner MR
    Expert Rev Mol Diagn; 2010 Jan; 10(1):75-87. PubMed ID: 20014924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tailoring Ras-pathway--inhibitor combinations for cancer therapy.
    Blum R; Kloog Y
    Drug Resist Updat; 2005 Dec; 8(6):369-80. PubMed ID: 16356760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New druggable targets in the Ras pathway?
    Matallanas D; Crespo P
    Curr Opin Mol Ther; 2010 Dec; 12(6):674-83. PubMed ID: 21154159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the RAS-dependent chemoresistance: The Warburg connection.
    Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
    Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting RAS signalling pathways in cancer therapy.
    Downward J
    Nat Rev Cancer; 2003 Jan; 3(1):11-22. PubMed ID: 12509763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Progress in the study of antitumor drug targeting on the Ras signaling pathway].
    Zhu YJ; Jiang FC
    Yao Xue Xue Bao; 2009 Jan; 44(1):1-10. PubMed ID: 19350814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugging RAS: Know the enemy.
    Papke B; Der CJ
    Science; 2017 Mar; 355(6330):1158-1163. PubMed ID: 28302824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving Prospects for Targeting RAS.
    Singh H; Longo DL; Chabner BA
    J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the RAS oncogene.
    Takashima A; Faller DV
    Expert Opin Ther Targets; 2013 May; 17(5):507-31. PubMed ID: 23360111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cdc42 Signaling Pathway Inhibition as a Therapeutic Target in Ras- Related Cancers.
    Aguilar BJ; Zhou H; Lu Q
    Curr Med Chem; 2017; 24(32):3485-3507. PubMed ID: 28571533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEK inhibitors: a patent review 2008 - 2010.
    Trujillo JI
    Expert Opin Ther Pat; 2011 Jul; 21(7):1045-69. PubMed ID: 21548849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of the development of Ras inhibitors.
    Shima F; Matsumoto S; Yoshikawa Y; Kawamura T; Isa M; Kataoka T
    J Biochem; 2015 Aug; 158(2):91-9. PubMed ID: 26100833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic strategies to target RAS-mutant cancers.
    Ryan MB; Corcoran RB
    Nat Rev Clin Oncol; 2018 Nov; 15(11):709-720. PubMed ID: 30275515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to make an undruggable enzyme druggable: lessons from ras proteins.
    Sayyed-Ahmad A; Gorfe AA
    Adv Protein Chem Struct Biol; 2020; 122():181-202. PubMed ID: 32951811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking Ras inhibition as an antitumor strategy.
    Marín-Ramos NI; Ortega-Gutiérrez S; López-Rodríguez ML
    Semin Cancer Biol; 2019 Feb; 54():91-100. PubMed ID: 29409706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.